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Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine in vulnerable populations 
reduces malaria morbidity in Africa, but resistance mutations in the parasite dhps gene (combined with 
dhfr mutations) threaten its efficacy. We update a systematic review to map the prevalence of K540E 
and A581G mutations in 294 surveys of infected humans across Africa from 2004-present. Interpreting 
these data is complicated by multiclonal infections in humans, especially in high transmission areas. 
We extend statistical methods to estimate the frequency, i.e. the proportion of resistant clones in the 
parasite population at each location, and so standardise for varying transmission levels. Both K540E 
and A581G mutations increased in prevalence and frequency in 60% of areas after 2008, highlighting 
the need for ongoing surveillance. Resistance measures within countries were similar within 300 km, 
suggesting an appropriate spatial scale for surveillance. Spread of the mutations tended to accelerate 
once their prevalence exceeded 10% (prior to fixation). Frequencies of resistance in parasite populations 
are the same or lower than prevalence in humans, so more areas would be classified as likely to benefit 
from IPT if similar frequency thresholds were applied. We propose that the use of resistance frequencies 
as well as prevalence measures for policy decisions should be evaluated.
Intermittent preventive treatment in infants (IPTi) and pregnant women (IPTp) with sulphadoxine–pyrimeth-
amine (SP) is recommended by the World Health Organization (WHO) in areas of moderate-to-high malaria 
transmission in sub-Saharan Africa but wide regional variations in drug resistance critically influence the success 
of this intervention. In East Africa, parasites have a higher threshold of SP tolerance than those found in West 
Africa. Mutations in dihydrofolate reductase (Pfdhfr gene) confer resistance to pyrimethamine while mutations 
in the dihydropteroate synthetase (Pfdhps gene) confer resistance to sulphadoxine. The association between these 
mutations and SP efficacy is complex1 and is affected by factors such as individuals’ immunity to malaria2, but 
the following associations have been found. In East Africa a triple mutant dhfr allele containing N51I, C59R, 
and S108N mutations combined with a double mutant dhps (A437G + K540E) (together known as the quintu-
ple mutant) is associated with clinical and parasitological SP treatment failure3–6, and reduces the prophylactic 
period provided by SP6. However, protection by IPT with SP in pregnant women against low birth weight out-
comes is sustained even in areas with high levels of the quintuple mutant6–9, and infants benefit from IPT in areas 
with intermediate (~50% prevalence), though not high (>90% prevalence) levels of the quintuple mutant10, 11. In 
certain East African foci, resistance has intensified because parasites have acquired an additional dhps A581G 
mutation. One such area reported 86% clinical failure12 and loss of protective efficacy of IPTi13 and IPTp13, 14, and 
a meta-analysis concluded that IPTp efficacy was reduced when the prevalence of the 581G mutation was over 
10%2, 14, 15. Hence the surveillance and reporting of 540E and 581G has a central role in IPTp-SP policy decisions.
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The WHO recommends IPTi with SP only where the prevalence of 540E among infected individuals is under 
50%10, and the WHO draft recommendations on IPTp recommend considering discontinuation of IPTp when 
the prevalence of 581G is over 10% and 540E is over 95%16. The prevalence of resistance mutations is defined as 
the proportion of infected humans who are carrying at least one mutant parasite clone. The prevalence is readily 
quantified from PCR analysis of the haploid parasite blood stage in fingerprick blood samples from infected 
humans. However, interpreting these data is complicated by individuals infected with multiple parasite clones, 
especially in areas of high transmission17, 18. The frequency of resistance in the parasite population, defined as 
the proportion of parasite clones which have a resistance marker, is usually not the same as the prevalence of 
resistance in infected humans (Fig. 1). For example, in a situation where the frequency of resistance in parasites is 
50%, the prevalence of resistance in humans will also be 50% if every infected individual carries only one parasite 
clone, but would be 75% if everyone carried 2 clones (assuming random distribution of clones) (Fig. 1). In mixed 
infections containing wild type and resistant parasites with more than 2 clones (a multiplicity of infection (MOI) 
>2), frequencies cannot be directly measured using standard PCR techniques, because these simply detect the 
presence or absence of resistant and wild type parasites, not their abundance19. For example in mixed infections 
with an MOI of 3, there could be 1 resistant clone and 2 wild type, or 2 resistant clones and 1 wild type. The unit 
of analysis for resistance frequency used throughout our study is a parasite clone, in line with previous analyses, 
since few studies to date use techniques which can quantify parasites of a particular genotype within a mixed 
infection20.
Measuring the frequency of resistance mutations in parasites as well as the prevalence in humans is impor-
tant because frequencies are more comparable when levels of malaria transmission and the number of clones in 
infected individuals vary across different areas or time points. Both prevalence and frequency of resistance may 
also be clinically relevant for IPTp and IPTi. Prevalence is an important indicator of the likelihood of individu-
als remaining parasite positive after treatment, which appears to be particularly important in pregnant women 
who are often already infected prior to pregnancy, and where increased duration of placental infection worsens 
outcomes21. In areas with the 581G mutation, one study suggested that SP-IPTp could actually increase parasite 
densities by clearing wild type parasites and thereby facilitating greater multiplication of these highly resistant 
parasites14, though this was not found elsewhere15, 22. However, in areas without the 581G mutation, the ability of 
SP to reduce parasitaemia and MOI in pregnant women without fully clearing all parasites may reduce anaemia 
and contribute to preventing low birth weight6, 23. If clearing some clones from a multiclonal infection is benefi-
cial, the proportion of parasite clones which are resistant, i.e. the frequency, may be important. The impact of IPT 
in infants is thought to be mainly due to providing prophylaxis against new infections inoculated by bites from 
infectious mosquitoes24, 25, and this probably also contributes to IPT impact in pregnant women, as evidenced 
by increased effect of more SP-IPTp doses after initial clearance of infection7. Mosquitoes harbour fewer parasite 
clones than humans, often only a single clone17, 18, 26. Therefore, the frequency of resistance in parasites might 
be a better indicator of the ability of SP to prevent new infections from mosquitoes rather than prevalence of 
resistance in humans although this has not been evaluated. Many studies have also found that clinical episodes 
of malaria result from acquiring a new parasite clone, even in individuals already asymptomatically infected with 
other clones27–30. This suggests that clearing particular clones rather than all parasites in an infection has a clinical 
Figure 1. The difference between the prevalence of resistance in the infected human population (% of 
individuals carrying at least one resistant parasite clone) and the frequency of resistance in the parasite 
population (% of parasite clones which are resistant). If each individual carries only one parasite clone (a 
multiplicity of infection (MOI) of 1) (A), then the frequency and prevalence of resistance are the same. However 
in most areas, particularly areas with high malaria transmission intensity, individuals carry multiple parasite 
clones, so that the frequency and prevalence of resistance are often not the same. For example, if everyone in 
an area carries 2 parasite clones (B), and the frequency of resistance in the parasite population is 50%, then 
the prevalence of resistance in humans would be 75% if clones are distributed randomly. The prevalence of 
resistance in humans is almost always higher than the frequency of resistance in the parasite population due 
to multi-clonal infections. In reality, individuals in a malaria-endemic area carry different numbers of parasite 
clones (which we allow for in the analyses presented in the Methods and Results sections).
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impact and therefore the frequency of resistant clones as well as the presence of any resistant clone within an 
infection may matter.
The frequency of resistance in parasites in a survey is often estimated by simply excluding mixed wild 
type-resistant infections from analysis, and presenting the proportion of remaining individuals who have a 
pure resistant infection. However, this can mean a considerable proportion of samples are excluded in areas of 
moderate-high transmission and medium resistance prevalence19, 31, and can be biased because the MOI distribu-
tions in pure resistant and pure wild type infections are not necessarily the same19. Several previous studies have 
developed other methods for estimating the frequency of resistance. When detailed data are available on the MOI 
together with presence of resistant and wild type parasites in individual infections, the frequency can be estimated 
by maximum likelihood32–35. These methods are ideal where such detailed data are available, however this is 
often not the case with routine surveillance data of molecular markers. This issue was noted as an unsolved chal-
lenge during previous molecular marker mapping exercises36, 37. Others proposed that where individual MOI data 
were not available, frequencies could be estimated from the observed proportion of mixed resistant-wildtype, 
all-resistant and all-wild type infections, and the mean population MOI, assuming a plausible MOI distribution 
(for example, Poisson)31, 38. This worked well on simulated data, and was also applied to field data in Uganda31. 
However, even mean MOI data are usually not available from sites with resistance surveillance data, and some-
times only the prevalence of resistance is reported, not the proportion of mixed resistant-wild type infections.
Here, we further develop these previously published methods in order to estimate the frequency of resistance 
mutations in the parasite population from the reported prevalence of resistance in infected humans in routine 
surveillance data, first validating our methods using a large, detailed dataset from southern Tanzania39, 40. We then 
update a systematic review of the prevalence of the 540E and 581G mutations in infected humans across Africa 
and apply our method to also estimate the frequency of these mutations in the parasite population in each area. 
We map mutation prevalence and frequency and quantify spatiotemporal trends in SP resistance.
Results
Distribution of 540E and 581G mutations: systematic review. We updated a systematic review41, 42  
of the distribution of dhps 540E and 581G mutations in Africa, including all published studies which assessed 
the prevalence of the mutation in P. falciparum-infected individuals in endemic areas (full data available in 
Supplementary data 1 and 2 and at www.drugresistancemaps.org). We excluded samples of patients recently 
treated with SP as part of the study. The previous review was completed in 2011 and the most recent samples in 
that review were collected in 2008 (the average time lag between sample collection and publication is 5 years41). 
The updated review includes studies published up to March 2016, although the most recent surveys reported 
in those publications were carried out in 2013. The review generated 182 new measures of the 540E mutation 
and 157 of the 581G mutation (Fig. 2A). Since 2008, three new countries measured a prevalence of 540E >50%: 
Sudan, Somalia and the Republic of the Congo, in addition to the nine countries already measuring this level of 
the resistance marker before 2008 (Fig. 2A). In only 6 of 32 countries were all samples wild type at the 540 locus; 
most were in West Africa where prevalence remained low in the large majority of samples (Fig. 2A). Thirteen of 
26 countries detected the 581G mutation (Fig. 2B). All these had already identified it in surveys from 2008 and 
earlier. Surveillance coverage generally improved, for example in the DRC, but remained sparse in parts of West 
Africa.
Estimating resistance frequency from prevalence measures: validation of methods. In the sys-
tematic review surveys, the prevalence of mixed resistant-wild type infections among infected individuals varied 
from 0 to 82%, indicating that the frequency of resistance in the parasite population might be different from the 
prevalence of resistance in humans in some areas. We sought to estimate frequencies in the parasite populations 
in each survey from the systematic review data by applying and developing existing methods19, 31, 32, 35. The main 
challenge was that the systematic review data mainly provide only summary measures on the prevalence of dhps 
mutations in humans in each survey, and no information on how many parasite clones were observed per person, 
whereas most of the existing methods for estimating frequency require detailed data for each individual on muta-
tions and their MOI. Furthermore, the imperfect sensitivity of PCR methods to detect all clones in an infection 
needed to be taken into account19.
First, we compared and validated methods for estimating frequencies from prevalence data using a test dataset 
for which we have detailed data for each individual on resistance markers and MOI. The test dataset is from 5191 
samples from cross-sectional surveys of individuals of all ages in 24 district level clusters in Tanzania in 2004 and 
200739 Individuals were not selected based on symptoms of malaria. We chose the 540E mutation for analysis 
because its frequency varied considerably across the study area and by year. We compared several methods and 
assumptions used for estimating frequency, each of which are defined fully in the Methods section and assigned a 
number. At first, for simplicity, we assumed that 100% of parasite clones are detected (this assumption is denoted 
by the letter A after the method number). Firstly, we estimated the frequency of 540E in each cluster and year 
using an existing method by Hastings et al. (Method 2A)32 which utilises the full information on resistance mark-
ers and MOI for each individual in the Tanzanian test dataset. We found that the estimated frequencies in the 
Tanzanian parasite populations were consistently lower than the prevalence of resistance mutations in humans, 
as expected (Figs 1 and 3A).
We next used several adjusted methods to estimate frequency without using the full data, to resemble sys-
tematic review data, to see how accurate these estimates can be, for example when we lack information on MOI 
or mixed infections. Frequency is commonly estimated simply by excluding mixed wild type-resistant infections 
from analysis and calculating the proportion of the remaining infections that are resistant (Method 1A). In the 
Tanzania test dataset this method gave relatively similar frequencies to those estimated from analysis of the full 
individual information (Method 2A, Fig. 3A and Table 1) but has the disadvantage that a considerable number of 
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mixed samples may be excluded from the analysis, up to ~60% per survey in this test dataset (Figure S2). There 
was also some bias in this frequency estimate because the mean MOI of pure resistant versus pure wildtype 
infections was 2.7 versus 3.3, respectively, which the method does not take into account. We next tried estimat-
ing frequencies in the Tanzanian dataset using the proportion of pure resistant, pure wild type and mixed wild 
type-resistant infections, but without using the individual MOI data for each person. Instead we used the method 
of Taylor et al.31, where it is assumed that we know only the population mean MOI, and we allow for the variation 
in MOI across infected people by assuming a Poisson distribution of the number of clones per person (Method 
3A). Frequencies estimated using this method 3A correlated well with the estimates made using the full individual 
MOI data (Method 2A, Fig. 3B and Table 1).
Figure 2. Prevalence of dhps (A) 540E and (B) 581G in infected individuals and estimated frequencies of (C) 
540E and (D) 581G mutations in parasite populations in Africa 2004–2008 (squares) and 2009–2013 (circles) 
(see also Supplementary data 1 and 2). Data point size is proportional to sample size, with most recent data 
on top. (A) 540E prevalence was assessed in 294 surveys in 32 countries since 2004, of which only 6 did not 
detect the mutant at all: Burkina Faso, Gambia, Côte d’Ivoire, Madagascar, Niger, Swaziland. Nine countries 
detected 540E prevalence >50%: Sudan, Somalia, the Republic of the Congo, Tanzania, Malawi, Kenya, DRC, 
Mozambique, Ethiopia, Rwanda, Uganda and Zambia. (B) 581G prevalence was assessed in 147 surveys in 26 
countries, of which 13 countries detected the mutation: Angola, Cameroon, Democratic Republic of the Congo, 
Ethiopia, Equatorial Guinea, Kenya, Malawi, Niger, Rwanda, Sudan, Tanzania, Uganda and Zambia. (C and 
D) Frequencies are shown only for surveys which reported the prevalence of mixed infections (27% of total 
surveys), or estimated frequency by excluding mixed infections from analysis (21%), or had zero prevalence 
(32%). Surveys which counted mixed infections as mutants (11%), or did not specify how mixed infections 
were dealt with (8%) were excluded. Frequencies are estimated using Method 5C (Methods section, equation 8), 
assuming the probability of detecting each clone was 0.54. Maps were generated in R software version 3.1.362, 61 
and are based on 180 publications (62 since 2011). Similar patterns are confirmed by an independent review of 
35 publications carried out after our review was complete63.
www.nature.com/scientificreports/
5SCIEnTIFIC RePORTS | 7: 7389  | DOI:10.1038/s41598-017-06708-9
However, even mean population MOI estimates are usually not available in the surveys in our systematic 
review. Therefore, we also tried estimating frequencies without any MOI data (Methods 4A and 5A). Instead we 
used the fact that the average number of parasite clones per person increases with malaria transmission inten-
sity43, which is more commonly measured. To characterise this relationship, we assembled 63 paired measures 
of mean MOI in infected individuals and malaria transmission intensity (Fig. 4). We used slide-prevalence of 
malaria in 2–10 year olds as the measure of transmission intensity, since this is most widely available44. A linear 
relationship of log mean MOI with logit slide prevalence in 2–10 year olds (p < 0.001) gave a good fit to the data 
(Fig. 4). Some molecular marker surveys measure slide-prevalence, and therefore this can be directly used to 
estimate mean MOI, but if they do not, slide-prevalence estimates are available from the Malaria Atlas Project 
across Africa for each year from 2000–2015 at a 5 × 5 km resolution44, 45. We estimated mean MOI for each cluster 
Figure 3. Estimating mutant frequencies in parasite populations: validation of different methods using 540E 
and MOI data from cross-sectional surveys of 5131 people in 2004 and 2007 in 24 divisions in Tanzania39. 
Ideally, frequencies are estimated using detailed data from all infected individuals on their MOI and whether 
an infection is pure resistant, pure wild type or mixed. We plot 540E frequencies estimated using only 
partial data, such as is more often available from routine surveillance of mutations (Methods 3–5), against 
frequencies estimated from this full dataset for each location (Method 2; x axis on all panels) : (A) black 
points: 540E frequencies estimated by excluding mixed infections (Method 1A vs Method 2A); yellow points: 
for comparison we also show the prevalence of any 540E mutation among infected individuals (B) blue 
points: 540E frequencies estimated from data on mixed infections and mean population MOI (Method 3A vs 
Method 2A); red points: 540E frequencies estimated from data on mixed infections but with no MOI data 
(Method 5A vs Method 2A), instead estimating mean MOI using the Malaria Atlas Project slide prevalence 
and the relationship in Fig. 4 (C) orange points: 540E frequencies estimated with no MOI data nor data on 
mixed infections, using data on resistance prevalence only (Method 8A vs Method 2A) (D) red points: 540E 
frequencies estimated with data on mixed infections but no MOI data when detection of clones is imperfect, 
either assuming clones are missed in high MOI infections (Method 5B vs Method 2B) or (blue points) clones 
have a constant probability of being missed in any infection (Method 5C vs Method 2C).
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and year in the Tanzania survey test dataset, using either slide-prevalence measured during the survey (Method 
4A) or estimated slide prevalence from the Malaria-Atlas Project44 in the same year as the survey (Method 5A). 
These mean MOI values were then used to generate a distribution of MOI in the population, assuming a Poisson 
distribution as before. Frequencies estimated using both these methods (Methods 4A & 5A) correlated very well 
with the estimates made using the full test dataset (Fig. 3B and Table 1). Using estimated rather than true mean 
MOI (Fig. 3B, Method 3A)) or the true slide prevalence (Method 4A) made negligible difference (Table 1), despite 
neither the MOI or slide-prevalence estimates being very well correlated with their true values (Supplementary 
Fig. S1). Assuming a negative binomial distribution for MOI instead of a Poisson distribution (Method 6), or 
allowing the mean MOI to vary during fitting (Method 7) or also produced negligible difference in frequency esti-
mates (Table 1). Together, the comparison of methods 2–7 indicate that the estimated frequencies are not highly 
sensitive to the assumed MOI distribution, confirming previous results31, 35. This shows that good frequency 
estimates can be obtained without needing MOI data for each survey.
We next tried estimating frequencies using data from all individuals, but assumed that we only know the 
prevalence of infections carrying at least one resistance marker (Method 8A), not the prevalence of mixed wild 
type-resistant infections, as is often the case with published molecular marker surveys (mixed infections may be 
counted as resistant). However, frequencies estimated using only this information differed considerably from 
frequencies estimated from the full individual dataset (Method 2A) (Fig. 3C and Table 1), indicating that knowing 
the proportion of mixed infections is important.
The analyses presented so far assume 100% detection of parasite clones. We further considered that some 
parasite clones may not be detected during laboratory measurement, for example due to low densities. This was 
found to be important in a previous analysis to improve fit to the data19. We incorporated imperfect detectability 
into the frequency estimation method which uses the full individual data (Method 2), as a baseline for com-
parison. We also chose to incorporate detectability into method 5 which estimated frequencies well using only 
information on the proportion of mixed infections and the Malaria-Atlas-Project-estimated slide prevalence, i.e. 
with the most parsimonious assumptions and data. We tested 3 different assumptions about detectability: (A) that 
100% of clones are detected, as described above, (B) following a published method by Hastings et al.19, that resist-
ant or wild type clones in an infection are not detected if they constitute less than a given proportion (the ‘geno-
typing sensitivity limit’) of the total clones or (C) that the probability of missing any clone is constant regardless of 
the MOI of an infection (similarly to Ken-Dror et al.35). We use these letters A, B and C to denote these different 
detectability assumptions. We first compared these different detectability assumptions when the frequencies were 
estimated from the full individual Tanzanian test dataset. Assumption C gave the best fit of the model to the test 
dataset (Method 2C), with the previously published method19 (Method 2B) fitting next best and the assumption 
of 100% detection (Method 2A) fitting worst (log likelihoods: −1616, −1772 and −2110, respectively). The prob-
ability of detecting each clone estimated by method 2C was 0.54 (95% CI 0.25–0.77), and the best fitting geno-
typing sensitivity limit in the published method (2B) was 0.33. Including imperfect detection improves the fit of 
the model to the proportion of mixed infections (Supplementary Fig. S2; Methods 2A, 2B and 2C). Estimating 
Figure 4. Relationship between slide-prevalence of infection in 0–15 year olds (PfPR0–15) and the mean 
multiplicity of infection (MOI) in infected individuals in 63 sites. Data (points) and model fit (black line). 
Data are: (blue) asymptomatic individuals in the test datset in Tanzania in 2004 and (red) 2007;58 (orange) 
data from a previous review in multiple sites43 containing both symptomatic and asymptomatic individuals; 
and (black) from symptomatic patients in Uganda64. 48 of the measures had simultaneous measures of 
slide-prevalence, while the other 15 were paired with an alternative measure of transmission intensity, the 
entomological inoculation rate (EIR, number of infectious bites per person per year). We converted the EIR 
values to slide-prevalence values in 0–15 year olds, using a previously published relationship60. Model fit (black 
line) is from linear regression of log MOI against the log odds of PfPR0–15. The best fitting relationship is log 
MOI = 1.082 + 0.185*logit(PfPR0–15). This is further confirmed with a similar relationship fitted in a separate 
review and mathematical modelling paper published after our analysis was complete65.
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frequency using imperfect detection models again worked well even if no MOI or slide-prevalence data were 
used (Methods 5B and 5C) (Fig. 3D and Table 1). In addition, we tried three further plausible extensions to 
the model with imperfect detection: (1) assuming that the probability of missing a clone increases linearly with 
MOI; (2) assuming that in multiclonal infections, a single dominant clone is detected with a higher probability 
than the other clones; (3) assuming there is geographical heterogeneity in the proportion of resistant clones. All 
these extensions slightly improved the fit of the model to the data (Supplementary methods), but as none clearly 
outperformed the others on this test dataset, we did not further apply these methods in this paper although they 
could be applied to detailed individual data in other settings.
540E and 581G frequency maps. Having tested and validated methods for estimating resistance frequen-
cies in parasite populations, we applied these to the systematic review survey data on the prevalence of resistance 
markers in infected humans to generate new frequency maps of 540E and 581G (Fig. 2C and D). Our analysis 
validation on the Tanzanian test dataset showed that frequencies can be estimated well without MOI data, instead 
estimating mean MOI for each survey population using a relationship between mean MOI and Malaria Atlas 
project-estimated slide-prevalence and assuming a Poisson distribution for MOI. However, it was important to 
have data on the proportion of mixed wild type-resistant infections, without which frequencies were poorly esti-
mated. The frequency estimation model which fit the test data best assumed that detection of parasite clones is 
imperfect and does not depend on MOI. We therefore applied the analysis method which incorporated all these 
aspects (Method 5C; see Methods section) to estimate frequencies in all surveys which had mutation prevalence 
greater than zero and which reported the prevalence of mixed infections (n = 126 surveys for 540E, n = 38 for 
581G). R code for estimating frequencies is provided in the Supplementary Information. Where the prevalence of 
resistance was zero, we assumed the frequency was also zero. The maps (Fig. 2C and D) also include sites where 
the original study estimated frequency by simply excluding mixed infections from analysis. For sensitivity anal-
ysis, we also varied the probability of detecting parasite clones, since the sensitivity of PCR methods is likely to 
vary between studies.
Frequencies of 540E and 581G in the parasite population gave a very different picture from the prevalence 
of 540E and 581G in humans in some surveys, with up to 40% absolute difference between measures, whilst in 
other surveys, the difference was small or zero (Fig. 5). When prevalence is low (<~5%), there are only small dif-
ferences from frequency estimates. When prevalence is high, for example >90%, in some surveys this is because 
the mutation is truly approaching fixation in the parasite population, and then frequency estimates are close to 
prevalence. In other surveys, this high observed prevalence simply reflects a high level of mixed infections in the 
















detection of parasite clones Other
5B √ √ Imperfect MOI-dependent 0.0031 This paper extended from32
5C √ √ Imperfect MOI-independent 0.0037 This paper




0.0061 This paper extended from31
5A √ √ 100% 0.0062 This paper extended from31





0.0071 This paper extended from31
3A √ √ 100% 0.0071 31
4A √ √ 100% 0.0083 This paper extended from31
8A √ 100% 0.0140 This paper extended from31
Table 1. Estimating mutant frequencies using different methods: validation using a test dataset from 
Tanzania39. Frequencies of the 540E mutation are estimated in 24 areas in 2 different years. We compare 
frequencies estimated from the full dataset with information on MOI and resistance markers for each individual 
(Method 2, see Methods) with frequencies estimated from partial summary data using different methods. We 
show mean squared error to quantify the difference between the two sets of estimates in each comparison. The 
methods are ordered by increasing mean squared error; lowest indicates more similar estimates. The column 
‘mixed infections’ indicates that data on the proportion of mixed wild type-resistance infections was used to 
estimate frequencies. ‘Slide prevalence’ indicates that mean MOI was estimated using the relationship in Fig. 4. 
‘Location’ indicates that longitude and latitude of the survey location were used to obtain estimates of slide-
prevalence from the Malaria Atlas Project, in order to estimate mean MOI using Fig. 4 45. Where imperfect 
detection of parasite clones was assumed, this was included when fitting to both the full and partial datasets 
(letters A to C after the Method number denote assumption about detection; see Methods. For example, in the 
first row, method 5B is compared to method 2B, in the 2nd row method 5C is compared to method 2C etc).
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and <90%, n = 56 surveys) the frequency was on average 9–10% lower than prevalence (depending on detection 
assumption). The maximum observed difference was 37%. Similarly, at intermediate prevalence of 581G (n = 20), 
frequency was 8–11% lower than prevalence. Varying assumptions about the sensitivity of detection of parasite 
clones did not change the estimated frequencies substantially (mean difference of 2.4% when changing sensitivity 
from 100% to 30% in Method 5C), although assuming imperfect detection improved the fit of the model to the 
proportion of mixed infections in the surveys (Supplementary Fig. S3).
If specified thresholds were used to classify areas as suitable for particular interventions, using frequencies 
rather than prevalence could give very different results. For example, of 38 surveys, 22 surveys had 581G preva-
lence over 10% whilst only 14–16 had 581G frequency over 10%. It is not known whether resistance frequencies 
correlate with outcomes of SP-based interventions such as IPT, but for a hypothetical example, had a 10% 581G 
frequency threshold been used to decide a local policy at the time they were done, an extra one third of survey 
results would have been under the threshold compared with a 10% 581G prevalence threshold. These particular 
results were from areas with high malaria transmission, with an estimated mean slide prevalence in 2–10 year olds 
(PfPR2–10) of 46% (range 28–64%) at the time of the surveys. Interestingly, using frequency rather than preva-
lence for a 50% 540E threshold (the current IPTi policy recommendation) would only cause 6 out of 126 survey 
results to be additionally under the threshold. This is because resistance generally spreads rapidly at intermediate 
prevalence so is only at these levels for a short time with only 13% of surveys showing a prevalence between 
30–70% (Fig. 5A).
Spatiotemporal trends in dhps mutations. Marked differences were seen in the relationship between 
540E and 581G in different regions (Fig. 6). In Eastern and Southern Africa, the 581G mutant is much more com-
mon where 540E prevalence is high: 52/58 of surveys which detected the 581G mutation had >60% prevalence of 
the 540E mutation (Fig. 6A). North-east Africa showed a similar relationship (Fig. 6C) despite the likely different 
genetic origin of these mutations46, 47. However, in West Africa, 581G was detected in 20% of surveys despite 540E 
prevalence and frequency being under 5% in all surveys in this region. 581G was also detected in areas where the 
540E mutation was absent (Fig. 6B).
The prevalence of mutations within countries was relatively similar for measures taken up to 300 km apart 
within a year of each other, however at greater distances the difference increased (Fig. 7). Frequencies were overall 
marginally more consistent over space than prevalence measures (mean squared difference of pairwise com-
parisons within countries being 0.044 for frequencies, versus 0.047 for prevalence measures) (Supplementary 
Fig. S4A). To look at changes in mutation prevalence and frequency over time, we grouped data by the largest sub-
national regions of each country (first administrative areas). In areas which had measures both before 2009 and 
afterwards (n = 35 for 540E and 17 for 581 G), 540E prevalence increased in 60% of areas, decreased in 20%, and 
stayed at zero in 20%. 581 G prevalence decreased in only 6% of areas, increased in 59%, and stayed at zero in 35%. 
The rate of change of mutation frequency or prevalence was highly variable between locations (Fig. 7C and D). 
Pairwise comparison of successive time points within each area showed a median increase in 540E prevalence 
of 5.2% (interquartile range (IQR) 0.2, 16.0%) per year (excluding pairs where the prevalence was zero at both 
times or already >90%). In some areas, frequency measures revealed different temporal patterns of resistance. For 
example, in Tanga, Tanzania, the frequency of the 581 G mutation increased more slowly than the prevalence of 
the mutation (Fig. 7B). In this area, the prevalence of the 540E mutation appeared to be close to saturation as early 
as 1995, remaining between 80–90% for 10 years. However the estimated 540 frequencies suggest only 55% of the 
parasite population had the mutation in 1995 and it was still increasing in frequency for the next 10 years with 
some fluctuations (Fig. 7C and Supplementary Fig. S4, light green lines). The median increase in 540E prevalence 
was generally slower when the mutation was at low levels: 1.8% per year when frequency began at <10%, versus 
Figure 5. Prevalence of (A) 540E and (B) 581G mutations in the systematic review data compared with 
frequencies in the parasite population estimated by different methods: simple counting of mutant samples 
excluding mixed infections (orange crosses; Method 1A); by assuming 100% detection of clones (blue circles; 
Method 5A); by assuming detection is independent of MOI (Method 5C) with a probability of detection 
per clone of 0.54 (black triangles); or 0.3 (red vertical crosses). Surveys were included in these figures if they 
detected the mutant and reported the prevalence of mixed wild type-resistant infections.
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6.1% increase per year when frequency began at levels >10% but <90%, consistent with the expected ‘S’ shaped 
growth curve of resistant parasites (e.g. as shown in Smith et al.48). The median rate of change of 581 G prevalence 
was lower than 540E at 1.1% (IQR −0.8, 3.0%), but this may reflect low initial prevalence (Fig. 7D). There were no 
clear differences in temporal trends by region or by calendar time.
Discussion
We find evidence for continued spread of dhps 540E and 581 G mutations in Africa since 2008, despite SP being 
withdrawn as first line treatment in the majority of countries before this time. Three new countries detected 540E 
at >50%. 581 G was not detected in any new countries since 2008, but the prevalence of both mutations increased 
in the majority of countries which had already detected these markers prior to 2008. These findings indicate ongo-
ing SP drug pressure, which may in part arise from IPTp and seasonal malaria chemoprophylaxis programmes, 
although IPTi has not had wide uptake49 and IPTp coverage remains poor in many areas50. However, recent mar-
ket surveys have shown continued high use of SP in several African countries, particularly in the private sector, 
with for example SP constituting 42% of all antimalarials purchased in Tanzania in 201451–53, suggesting it is still 
widely used for uncomplicated malaria treatment. The continued spread highlights the need for ongoing surveil-
lance, since IPTp with SP is being scaled up across Africa9, 49, 50. Our results suggest that sentinel sites could be 
spaced a maximum of 300km apart, and that surveillance should be conducted more frequently when mutation 
prevalence exceeds ~10% (but is not yet fixed).
We show that frequencies of resistance in the parasite population could be estimated well from standard 
aggregate survey data on resistance markers in infected humans (see Supplementary Information for the full R 
code), without individual data or MOI data, as long as the proportion of mixed wild type-resistant infections was 
reported. We mapped dhps mutation frequencies, giving a clearer picture of what is happening in the parasite 
population and enabling comparison across areas and time points with different transmission intensity and MOI 
distributions. Current IPTi policy is based on the prevalence of resistance markers in infected individuals, and 
the same is suggested for IPTp policy16. It will be critical to further characterise the relationships between clinical 
impact of IPTi and IPTp with SP and dhfr and dhps mutations and the biological mechanism of SP action54, and 
ongoing studies are addressing this issue. In the meantime, high prevalence of resistance markers may preclude 
implementation of IPTi (and potentially IPTp) in some areas. The clinical relevance of mutation frequencies as 
opposed to prevalence in humans requires further research (see Introduction for more discussion of this issue). 
We suggest that frequency might be an important indicator of drug prophylactic effect given the prevalence of 
monoclonal infections within mosquitoes, as well as indicating the chance of clearing particular clones within 
mixed infections, but this needs to be better characterised. Given these uncertainties, we suggest it would be 
worth re-evaluating data to inform whether frequency thresholds as well as prevalence thresholds could be useful 
for policy guidelines. Mixed wild type-resistant infections, which create the difference between prevalence and 
frequency measures, are most common in high transmission settings, exactly where IPTp and IPTi have the high-
est public health impact. Frequency provides a lower threshold, as it is equal to or lower than prevalence, therefore 
the intervention would be recommended in more areas. For example, in our systematic review, we found that 
33% more surveys had 581 G mutations under a 10% frequency threshold compared with a 10% 581 G prevalence 
threshold. However more research would be needed to identify whether frequencies are informative and if so, 
what a suitable frequency threshold would be.
Figure 6. Relationship between prevalence of 540E and 581G mutations when measured in the same 
individuals in (A) Eastern and Southern Africa (n = 172), (B) West Africa (n = 50), (C) Northeast Africa 
(n = 15) using surveys from 1988–2013. Mixed infections contribute to some of these measures, therefore the 
haplotype is unknown for most samples (i.e. the two mutations could be present together on one parasite or 
separately on different parasites). The sample size for assessing the prevalence of the two mutations was not 
always identical, usually due to different PCR success rates. Data in Eastern and Southern Africa were from the 
Democratic Republic of the Congo, Kenya, Mozambique, Malawi, Rwanda, Tanzania, Uganda, South Africa and 
Zambia; in West Africa from Angola, Benin, Burkina Faso, Côte d’Ivoire, Cameroon, Ghana, Equatorial Guinea, 
Mali, Mauritania, Niger and Senegal; and Northeast Africa from Ethiopia, Sudan and Somalia.
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Whilst using frequency measures increases the comparability of surveys where transmission intensities were 
different, there are additional factors that we did not control for. The age of individuals in each survey varied 
considerably and is likely to influence the probability that someone carries resistant parasites, since intake of 
treatment is different across age groups39. Furthermore MOI varies by age55. Another potential confounder is that 
some surveys include largely asymptomatic malaria infections in the community, whilst others recruit patients 
with symptomatic malaria. Clinical samples may have higher levels of resistance, probably reflecting treatment 
in the informal sector before seeking care. Further work to quantify the impact of these other factors would be 
beneficial to standardise resistance measures. The test dataset from Tanzania that we used to validate our methods 
for estimating frequencies was a survey of asymptomatically infected individuals of all ages. We cannot be sure 
how accurate the method is when applied to different samples. However, similar methods worked well on clinical 
samples in other settings31.
We did not estimate haplotypes at the 540 and 581 loci because we did not have individual data and the 
degree of linkage disequilibrium is unknown. In East Africa, 581 G usually occurs together with 540E47, but in 
West Africa, 581 G was detected in the absence of 540E. The public health implications of the latter genotype are 
unclear and further research is required to characterise its phenotype. We also did not map dhfr genes, since these 
are not the focus of current policy10 and few studies reported the full dhfr and dhps haplotypes. Several methods 
have been developed to estimate haplotypes of parasites, which employ efficient methods such as Markov-chain 
Figure 7. Spatiotemporal variation in 540E and 581G prevalence. (A) Different spatial scales. We compared 
prevalence of the same mutation in the same country between surveys done within 1 year of each other. We plot 
the pairwise distance between the surveys against the absolute difference in prevalence of the mutation. Blue 
squares indicate the proportion of survey pairs in which the difference in mutation prevalence was less than 
10%. (B) Comparison of 581G frequency (triangles, dashed line) and prevalence (circles, solid line) in Tanga, 
Tanzania. Temporal trends in (C) 540E and (D) 581G prevalence. We compared successive measures within 
the same first administrative area which were <100km apart. Supplementary Fig. S4 shows the same results for 
frequency measures. Comparisons of two zero prevalence measures are excluded in all panels.
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Monte Carlo or Expectation-Maximization algorithms to maximise the likelihood31, 33, 35, but these all require 
individual patient data on MOI and multiple resistance markers. Ideally future resistance surveillance studies 
would measure MOI and estimate frequencies as part of the routine analysis.
Rapid advances in genetics and genetic analysis are improving techniques for measuring MOI56 and resistance 
frequencies within infected individuals, enabling quantification of parasites with different genotypes and distin-
guishing haplotypes in mixed infections57, 58. Whole genome data can be used to estimate MOI, for example using 
the estMOI software59. These techniques would provide extremely useful data but may not be available for routine 
surveillance of resistance markers for some time. The analyses presented in this paper show that robust estima-
tion of frequencies of single SNPs is possible from routine surveillance data without more resource-intensive 
molecular methods. These methods can be applied in future to standardise data on other resistance markers, in 
particular artemisinin resistance-associated mutations at kelch 13 and mutations conferring resistance to partner 
drugs in artemisinin combinations therapies, such as the emerging piperaquine-resistant strains in Cambodia 
which represent a severe public health threat.
Methods
Systematic review. We searched PubMed in March 2016 using the terms “malaria” and at least one of 
“dhps”, “pfdhps”, “540” or “581”, screening all studies published from 2011 onwards, when the previous systematic 
review was completed. We included studies which reported the prevalence or frequency of the 540E and/or 581G 
mutation in P. falciparum-infected individuals in a specific geographical area and the date of sampling. We col-
lected information on the location, date, sample size, reporting of mixed infections and age range.
Data. Full details of the test dataset used to compare different methods for estimating frequency are given 
in Pearce et al.39. In brief, survey data were from cross-sectional surveys conducted in 2004 and 2007 during a 
cluster-randomized trial of IPT with SP in infants. The intervention was implemented in 2005. Blood samples 
were collected on filter paper, and mutations at codon 540 of the dhps gene were detected by polymerase chain 
reaction (PCR) sequence-specific oligonucleotide probing (SSOP). Infections were counted as mixed if peaks 
could be detected above the noise threshold. MOI was assessed by polymorphisms in microsatellite markers 
PolyA, PfPk2, and TA109, and was calculated as the maximum number of observed variants.
Estimates of slide-prevalence in 2–10 year olds were taken from raster files published by the Malaria Atlas 
Project45. For each of the 24 clusters in the IPTi trial and for each survey in the systematic review, estimates were 
extracted using the year and longitude-latitude of the survey location. In order to estimate mean MOI in the area 
using the relationship in Fig. 4, these were converted to estimates of slide-prevalence in 0–15 year olds using a 
previously published model60.
Analysis: estimating frequency. The frequency of resistance p is defined as the proportion of parasite 






where ci is the number of resistant clones and ni is the total number of clones in individual i. The prevalence 
of resistance Prew(res) is defined as the proportion of infected humans who are carrying at least one resistant 
parasite clone. The relationship between the prevalence of resistance in humans Prev(res) and the frequency of 
resistance in the parasite population p, following Hastings et al.19 is:
∑= − −
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where n is the MOI of each individual infection, p is the frequency of resistance and dn is the proportion of 
samples which have an MOI of n. The prevalence of the wildtype Prev(wt) is calculated using the same equation, 
replacing the frequency of resistance p with the frequency of the wild type (1 − p). The proportion of human with 
mixed wildtype-resistant infections P(mix) is calculated from these as:
= + −P mix Prev res Prev wt( ) ( ) ( ) 1 (3)
The proportion of infections with all wild type P(wt) or all resistant parasites P(res) is calculated by subtracting 
P(mix) from Prev(wt) or Prev(res), respectively.
The frequency which maximised the likelihood of the observed prevalence of a molecular marker in any given 
survey was estimated, contrasting methods which make different assumptions and also those which use detailed 
individual datasets versus those which use various summary measures more often available from published sur-
veys. The details of each method and the data used by each are as follows:
Method 1. Frequency is estimated simply by excluding mixed wild type-resistance infections from analysis and 
calculating the proportion of infections which contain only resistant clones (all-resistant infections). This assumes 
that the distribution of MOI is the same in all-resistant as in all-wild type infections. It results in a lower sample 
size for estimating frequency.
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Method 2. The published Malhaplofreq algorithm32 which uses the full data where MOI and presence/absence 
of resistance markers is known for each individual (this was applied to the test dataset from Tanzania only). Here 
dn is simply the observed proportion of individuals with a given MOI in the data.
Method 3. This method can be applied when only the prevalence of resistant and mixed infections, and the mean 
MOI in the study population are known. Here, dn is assumed to follow a zero-truncated Poisson distribution, 
which would be observed when individuals are each infected at the same average rate. The zero-truncation allows 
for only analysing data from infected individuals. We fit the equations for P(res), P(wt) and P(mix) described 
above to the observed proportion of all-resistant, all-wildtype and mixed infections in each survey, respectively, 
using multinomial likelihood. These assumptions are similar to those used by Taylor et al.31 but because we ana-
lyse only one SNP at a time, we could use standard methods to maximise the likelihood.
Method 4. As method 3, except the sample mean MOI is unknown whilst the local slide-prevalence of malaria 
is known. We estimate mean MOI using the relationship in Fig. 4.
Method 5. As method 3, but the mean MOI and the local slide prevalence are unknown. We use estimated 
slide-prevalence from the Malaria Atlas Project based on the location and year of the survey44.
Method 6. As method 5, but dn is assumed to follow a zero-truncated negative binomial distribution where some 
individuals are at higher risk of infection than others, assuming a relatively high level of variation (dispersion 
parameter = 0.5).
Method 7. As method 5, but the mean MOI, as well as the frequency, is allowed to vary during the fitting 
procedure.
Method 8. As method 5, but the proportion of mixed infections is unknown, only the prevalence of resistance 
(counting mixed infections as resistant) is known. We fit equation 2 to the observed prevalence of resistance in 
each survey using binomial likelihood.
For each of the methods 2–8, we further assessed three different assumptions about the sensitivity of detection 
of parasite clones:
A) Perfect 100% sensitivity.
B) That the probability of detecting a clone is dependent on the MOI of the infection, as described in the 
method by Hastings et al.32. Minority clones present at a density under a ‘genotyping sensitivity limit’ in mixed 
infections are assumed to remain undetected. This method modifies equation 2 to compute prevalence, calculat-
ing which clones would be detected in each possible SNP combination:
∑ ∑= −
= =









where v is 0 if c/n is less than the genotyping sensitivity limit and 1 otherwise. We varied the assumed genotyping 
limit simultaneously with the frequency to maximise the likelihood of the observed data.
C) That the probability of detecting a clone is independent of the MOI of the infection. We assumed that 
each clone, resistant or wild type, has a certain probability q of being detected, and calculated the proportion of 
resistant infections as follows. The probability of an all-resistant infection for a given value of c is the probability 
that all susceptible clones are missing multiplied by the probability that at least one resistant clone is non-missing
= − − −−P res n c q q( , ) (1 ) (1 (1 ) ) (5)n c c
Summing over all possible values of c
∑= − − − −
=
− −( )P res n nc p p q q( ) (1 ) ((1 ) (1 ) ) (6)c
n
c n c n c n
1
Equation 6 can be simplified (see Supplementary methods) to:
= + − − − −P res n p p q q( ) ( (1 )(1 )) (1 ) (7)n n
and when the assumption is made of a Poisson-distributed MOI with mean µ:
= −µ µ+ − − − −P res e e( ) (8)p p q q( (1 )(1 ) 1)
When fitting to the Tanzanian dataset, we estimated p and q simultaneously, allowing p to be different in each 
cluster and year but assuming q was constant. We obtained confidence intervals using profile likelihood. The sen-
sitivity of methods used to detect MOI is much higher than the methods used to detect resistance markers39, and 
therefore we assumed no effect of imperfect detection on MOI measures.
For each analysis we specify which of the methods 1–8 is used by its number, and which detectability assump-
tion is used by the letters A, B and C.
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